title: Epidermal growth factor in urine of nonpregnant women and pregnant women throughout pregnancy and at delivery.
abstract: Human epidermal growth factor (EGF) concentrations were measured by a specific solid phase RIA in random urine samples collected throughout the menstrual cycle of normal menstruating women (n = 8), women with tubal sterilization (n = 6), women taking a low dose oral contraceptive (n = 5), and women throughout pregnancy (n = 52) and delivery (n = 35). There were no differences in EGF concentrations between the proliferative and secretory phases of the menstrual cycle (P greater than 0.05). Normal menstruating women had higher urinary EGF concentrations [mean +/- SE, 37.2 +/- 6.0 micrograms/g creatinine (4.23 +/- 0.68 ng/mumol)] than women with tubal sterilization [32.7 +/- 4.0 (3.71 +/- 0.45)] or women taking a low dose oral contraceptive [19.5 +/- 6.0 (2.21 +/- 0.68)], but the differences were not significant (P greater than 0.05). During pregnancy, urinary EGF concentrations increased linearly from 6-20 weeks gestation (r = 0.76; P less than 0.001), then declined toward term (r = -0.71; P less than 0.001). EGF concentrations in early pregnancy (less than 12 weeks) or at term did not differ significantly from those in normal menstruating women (P greater than 0.05). For women delivering normal, appropriate for gestational age (AGA) infants, there was no correlation between urinary EGF concentrations and fetal weight or sex (P greater than 0.05). Urinary EGF concentrations in women delivering normal AGA infants [52.7 +/- 2.5 (5.98 +/- 0.28); n = 16] did not differ significantly (P greater than 0.05) from those in women with class A/B diabetes [41.9 +/- 2.8 (4.76 +/- 0.31); n = 6] or women delivering twins [45.6 +/- 2.6 (5.18 +/- 0.29); n = 8] with a greater fetoplacental mass. However, women delivering an intrauterine growth-retarded fetus with decreased fetoplacental mass had lower urinary EGF concentrations (24.9 +/- 2.2 (2.83 +/- 0.25); n = 5] than women with normal AGA infants (P less than 0.01). The significance of the rise in the urinary EGF concentration late in the second trimester and lower urinary EGF concentrations in women delivering intrauterine growth-retarded infants is not known, but may reflect an important physiological role for EGF in fetal-maternal hormonal interaction and development.
authors.affiliation: Department of Obstetrics and Gynecology, University of Cincinnati, Ohio 45267-0526.
authors.forename: G E
authors.initials: GE
authors.lastname: Hofmann
authors.forename: C V
authors.initials: CV
authors.lastname: Rao
authors.forename: M J
authors.initials: MJ
authors.lastname: Brown
authors.forename: L F
authors.initials: LF
authors.lastname: Murray
authors.forename: G S
authors.initials: GS
authors.lastname: Schultz
authors.forename: T A
authors.initials: TA
authors.lastname: Siddiqi
mesh_terms: D000293:Adolescent; D000328:Adult; D003274:Contraceptive Devices, Female; D003276:Contraceptives, Oral; D004815:Epidermal Growth Factor / Q000652:urine*; D005260:Female; D005317:Fetal Growth Retardation / Q000652:urine; D006801:Humans; D007743:Labor, Obstetric / Q000652:urine*; D008597:Menstrual Cycle; D011247:Pregnancy / Q000652:urine*; D013246:Sterilization, Tubal; D014427:Twins
chemical_list: D003276:Contraceptives, Oral; D004815:Epidermal Growth Factor